Sign in →

Test Code ADALP Adalimumab Quantitative with Antibody, Serum


Ordering Guidance


If there is a known justification for performing both quantitation and antibody levels, this is the correct test to order. If there is not a known reason to perform the antibody levels component, consider ADALX / Adalimumab Quantitative with Reflex to Antibody, Serum. ADALX testing begins with adalimumab quantitation and only performs testing for antibodies when the quantitation results are 8.0 mcg/mL or less.



Specimen Required


Patient Preparation: For 12 hours before specimen collection, patient should not take multivitamins or dietary supplements (eg, hair, skin, and nail supplements) containing biotin (vitamin B7).

Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1.0 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial


Secondary ID

620309

Useful For

Therapeutic drug monitoring of adalimumab concentration and antibody levels

Profile Information

Test ID Reporting Name Available Separately Always Performed
QNADL Adalimumab QN, S Yes, (ADALX) Yes
ABADL Adalimumab Ab, S No Yes
INTAD Adalimumab Interpretation No Yes

Method Name

Enzyme Linked Immunosorbent Assay (ELISA)

Specimen Type

Serum

Specimen Minimum Volume

0.7 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 28 days
  Frozen  28 days

Reject Due To

Gross hemolysis OK
Gross lipemia OK
Gross icterus OK
Heat-treated specimens Reject

Reference Values

ADALIMUMAB QUANTITATIVE:

Limit of quantitation is 0.8 mcg/mL. Optimal therapeutic ranges are disease specific.

 

ADALIMUMAB ANTIBODY:

<14.0 AU/mL

Interpretation

Adalimumab quantitation is generally performed in conjunction with immunogenicity assessment for antibodies to adalimumab (ATAs). Most often, this testing is ordered for patients with inflammatory bowel disease (IBD) who are on adalimumab therapy and who are experiencing loss of response (reactive monitoring),(6), but the testing may be ordered for anyone on adalimumab-even when treatment is going well (proactive monitoring).(7-9)

 

Results from adalimumab and ATAs testing play an important role in patient management. In the setting of loss of response to adalimumab therapy for adults with active IBD, a clinical decision tool from the American Gastroenterology Association (6,10,11) suggests the following scenarios for a blood draw that occurred at trough, ie, immediately before the next injected dose:

-For patients who have undetectable or low concentrations of adalimumab (<8 mcg/mL) but no detectable ATAs, the patient care team may choose to increase the dose of adalimumab in an attempt to increase the amount of the drug in circulation.

-If the patient has subtherapeutic adalimumab concentrations (<8 mcg/mL) in the presence of an ATA, the patient care team may switch the patient to another tumor necrosis factor inhibitor.

-For patients with increased trough concentrations of adalimumab (therapeutic or greater), whether an ATA is present or not, it may be necessary to switch the patient to a therapy with a different mechanism of action such as the anti-alpha 4-beta-7-integrin antibody vedolizumab or the IL12/IL23 antibody ustekinumab.

-Low trough concentrations may be correlated with loss of response to adalimumab.

 

Adalimumab concentration results above 35 mcg/mL are suggestive of a blood draw at a timepoint in treatment other than trough.

 

Test interpretation relies on clinical presentation and may differ from the statements above, which were designed for adults with IBD experiencing loss of response. For individuals on adalimumab therapy for other conditions such as rheumatoid arthritis, or pediatric patient populations or proactive monitoring, drug concentration therapeutic targets and patient management decision may be individualized. When both the drug quantitation and anti-drug-antibodies are ordered, an interpretive guide is offered below.

 

Adalimumab quantitation, mcg/mL

ATA, AU/mL

Comment

<8

Negative

Absence of detectable antibody-to-adalimumab (ATA). Low concentration of adalimumab (ADL) may be attributable to other parameters related to adalimumab clearance.

<8

Positive

Presence of antibody-to-adalimumab (ATA) detected, which correlates with low concentration of adalimumab (ADL). ATAs may be associated with increased clearance and lower circulating concentrations of ADL.

8.1-15

Negative

Absence of detectable antibody-to-adalimumab (ATA)

 

At this concentration of adalimumab (ADL), a low-titer (50-150 AU/mL) or moderate titer (150-500 AU/mL) ATA cannot be excluded. However, the presence of a high-titer ATA (≥500 U/mL) is unlikely.

 

If there is clinical suspicion for a low-titer ATA, suggest submission of a new sample obtained at trough.

 

This test has demonstrated drug tolerance up to 40 mcg/mL for ATAs ≥500 AU/mL, up to 15 mcg/mL for ATAs between 150-500, and up to 8 mcg/mL ADL for ATAs between 50-150 AU/mL.

 

Low or moderate positive

(14-499)

Presence of antibody-to-adalimumab (ATA) detected. At this concentration of adalimumab (ADL), the detected titer of the ATA may be modestly underestimated.

 

This test has demonstrated drug tolerance up to 40 mcg/mL for ATAs ≥500 AU/mL, up to 15 mcg/mL for ATAs between 150-500, and up to 8 mcg/mL ADL for ATAs between 50-150 AU/mL.

 

High positive (≥500)

Presence of antibody-to-adalimumab (ATA) detected.

 

This test has demonstrated drug tolerance up to 40 mcg/mL for ATAs ≥500 AU/mL, up to 15 mcg/mL for ATAs between 150-500, and up to 8 mcg/mL ADL for ATAs between 50-150 AU/mL.

>15

Negative

At this concentration of adalimumab (ADL), a low (50-150 AU/mL) or moderate titer (150-500 AU/mL) ATA cannot be excluded. The presence of a high-titer ATA (≥500 U/mL) is unlikely but cannot be completely excluded.

 

If there is clinical suspicion for an ATA, suggest submission of a new sample obtained at trough, preferably during the maintenance phase of therapy.

 

This test has demonstrated drug tolerance up to 40 mcg/mL for ATAs ≥500 AU/mL, up to 15 mcg/mL for ATAs between 150-500, and up to 8 mcg/mL ADL for ATAs between 50-150 AU/mL.

 

Low positive

(14-149)

 

Presence of antibody-to-adalimumab (ATA) detected. At this concentration of adalimumab (ADL), the detected titer of the ATA is likely underestimated.

 

Suggest submission of a new sample obtained at trough, preferably during the maintenance phase of therapy.

This test has demonstrated drug tolerance up to 40 mcg/mL for ATAs ≥500 AU/mL, up to 15 mcg/mL for ATAs between 150-500, and up to 8 mcg/mL ADL for ATAs between 50-150 AU/mL.

 

Moderate positive

(150-499 U/mL)

Presence of antibody-to-adalimumab (ATA) detected. At this concentration of adalimumab (ADL), the detected titer of the ATA may be underestimated.

Suggest submission of a new sample obtained at trough, preferably during the maintenance phase of therapy.

This test has demonstrated drug tolerance up to 40 mcg/mL for ATAs ≥500 AU/mL, up to 15 mcg/mL for ATAs between 150-500, and up to 8 mcg/mL ADL for ATAs between 50-150 AU/mL.

 

High positive (≥500)

Presence of antibody-to-adalimumab (ATA) detected.

 

This test has demonstrated drug tolerance up to 40 mcg/mL for ATAs ≥500 AU/mL, up to 15 mcg/mL for ATAs between 150-500, and up to 8 mcg/mL ADL for ATAs between 50-150 AU/mL.

Method Description

Adalimumab Quantitation:

The adalimumab enzyme-linked immunosorbent assay (ELISA) is designed to determine the quantity of free adalimumab (therapeutic antibody against tumor necrosis factor-alpha: TNF-alpha) in serum samples. In a first incubation step, the free adalimumab from the sample is bound to the specific monoclonal anti-adalimumab antibody coated on the plate. To remove all unbound substances, a washing step is carried out. In a further incubation step, peroxidase-labeled antibody is added. Tetramethylbenzidine (TMB) is used as a substrate for peroxidase. Finally, an acidic stop solution is added to terminate the reaction. The color changes from blue to yellow. The intensity of the yellow color is directly proportional to the concentration of free adalimumab in the sample. A dose response curve of the absorbance unit (optical density: OD) verses concentration is generated, using the values obtained from standard. The concentrations of free adalimumab in the samples are determined directly from this curve.(Unpublished Mayo method)

 

Antibodies to Adalimumab:

An ELISA is used to determine the presence of antibodies against TNF-alpha blocker adalimumab (Amjevita and Humira). During sample preparation, the antibodies-to-adalimumab (ATA) are separated from the therapeutic antibody adalimumab using an acid dissociation to acquire free ATA. By adding the peroxidase conjugate (POD-therapeutic antibody adalimumab) and the tracer (biotinylated therapeutic antibody adalimumab), the unlabeled therapeutic antibodies are replaced, and the labeled antibodies can form a complex with the ATA. This complex binds via biotin to the streptavidin-coated microtiter plate. It is detected via the peroxidase conjugate with the peroxidase converting the substrate, TMB, to a blue product. The enzymatic reaction is stopped by adding an acidic solution. The samples convert from blue to yellow. The color change is measured in a photometer at 450 nm. The interpretation is made using the cut-off control.(Unpublished Mayo method)

Day(s) Performed

Monday, Wednesday, Friday

Report Available

3 to 6 days

Specimen Retention Time

14 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

CPT Code Information

80145

83520

LOINC Code Information

Test ID Test Order Name Order LOINC Value
ADALP Adalimumab QN with Antibodies, S 99781-7

 

Result ID Test Result Name Result LOINC Value
QNADL Adalimumab QN, S 86894-3
ABADL Adalimumab Ab, S 90779-0
INTAD Adalimumab Interpretation 77202-0

Forms

If not ordering electronically, complete, print, and send a Gastroenterology and Hepatology Test Request (T728) with the specimen.